Research use only. Nothing on this page is medical advice.
No peptide is proven to speed injury recovery in people. Ranked by evidence, BPC-157 comes first, TB-500 second, and the rest have even less.
- BPC-157 leads on animal data, with about 30 people in human pilots (1).
- TB-500 beat BPC-157 on tendon strength in the one rat test that compared them (2).
- The only peptide with real trial data for joint pain is semaglutide, an approved weight-loss drug (3).
- Reviewers advise against peptides as a replacement or add-on to standard orthopaedic care (4).
Jump to the ranking, which peptide fits which injury, what reviewers conclude, risks and rules or the FAQ.
The 8 peptides for injury recovery, ranked best to worst
How to read the table. Animals: studies in rodents or other animals. Skin only: human trials outside injuries. Hormones only, Lab only, No injectable data: no injury data in people.
| Peptide | Best evidence | Main limit |
|---|---|---|
| 1BPC-157 | AnimalsRat studies across tendon, ligament, muscle, bone and gut (5). In people: about 30 patients in three small uncontrolled pilots, rated very low certainty (1) | More than 80% of studies come from one lab group (6) |
| 2TB-500 | AnimalsIn one 32-rat Achilles test, TB-500 reached significance on tendon strength and BPC-157 did not (2). TB-500 is a 7-amino-acid fragment of thymosin beta-4, and human work is on the full-length protein in eye, skin and heart (5) | No human musculoskeletal trial of TB-500 (5) |
| 3GHK-Cu | Skin onlyHuman trials cover skin and wrinkles. Lab and animal work reports more collagen and faster wound closure (7) | No clinical data for tendon, muscle or joint repair (8) |
| 4CJC-1295 and ipamorelin | Hormones onlyOne CJC-1295 injection raised growth hormone for 6 days or more and IGF-1, a growth signal made in response to it, for 9 to 11 days in healthy adults (9). Reviews class both as investigational for musculoskeletal use (10) | FDA lists serious adverse events for both (11) |
| 5MGF and PEG-MGF | Lab onlyCell and rodent work. One lab could not reproduce MGF peptide effects on muscle cells or stem cells (12) | No published human trial. Banned in sport (13) |
| 6Follistatin-344 | No injectable dataNo human trial of injected follistatin. Human data are gene therapy trials in a handful of patients with muscle disease (14) | Banned in sport (13) |
| 7KPV | Lab onlyHealing data come from gel and animal gut work. FDA has found no human exposure data (11) | Listed for pharmacy compounding, which is not approval (15) |
| 8AHK-Cu | Lab onlyOne study measured hair follicle growth in dishes (16) | No wound or tissue repair data |
Want the skin and wound side? See the top 5 healing peptides. Comparing the two leaders? Read BPC-157 vs TB-500. Looking at nerve damage instead? See ARA-290.
Which peptide fits which injury?
| Injury | Best-studied option | What the evidence shows |
|---|---|---|
| Tendon, such as Achilles | BPC-157, TB-500 | One 32-rat Achilles head-to-head. No human controlled trial (2, 5) |
| Ligament | BPC-157 | Rat studies only (5) |
| Muscle tear | BPC-157 | A rat study of quadriceps torn off the bone reported better walking and less leg stiffness (contracture) with oral BPC-157 (17) |
| Bone | BPC-157 | Animal studies. In people, bone health data are modest at best (4) |
| Knee osteoarthritis pain | Semaglutide (approved for obesity) | 68-week trial, 407 adults with obesity: more weight loss and less knee pain than placebo (3). Cartilage repair is unproven (10) |
| After surgery | Collagen-derived injectables | Small single-center human studies show early symptom benefits (10) |
| Muscle loss during rehab | CJC-1295, ipamorelin | Hormone levels rise. No injury outcome trials (9, 10) |
For tendons, see peptides for tendon repair. For joints, see best peptides for joint pain and peptides for arthritis.
What do orthopaedic reviewers conclude?
- A 2026 sports medicine review found 67% of studies were in animals. Human studies were a handful, mostly without strong controls, and peptides should not replace or add to standard care (4).
- A 2026 orthopaedic review found no FDA-approved musculoskeletal use for BPC-157, thymosin beta-4 or TB-500, and said routine clinical use cannot be recommended (5).
- A 2026 systematic review of BPC-157 in people said it should not be used clinically outside regulated, high-quality trials (1).
What are the risks and rules?
- Product quality. Identity, purity, concentration and sterility are all concerns with commercial products (5).
- Skipping diagnosis. A tear, nerve problem or unstable joint needs a clinician. Peptides do not tell you what is injured.
- Feeling better is not healing. Pain can ease before the tissue is ready, so a return to training too early can set you back.
- Law. None of these has an FDA-approved musculoskeletal use (5). HHS announced an interim policy on 28 October 2026 for pharmacy compounding of six peptides, including BPC-157 and TB-500, and it is not approval (15).
- Sport. WADA bans BPC-157 under S0 (non-approved substances) and TB-500 under its growth-factor class, so tested athletes cannot use either (13).
Our long-term safety guide covers the full risk picture, and how to verify a COA shows how to match a vial to its lab report.
Where to buy injury recovery peptides
Each guide compares sellers by what their lab reports show: best place to buy BPC-157, best place to buy TB-500, where to buy GHK-Cu and best peptide vendors.
Injury recovery peptides FAQ
What is the best peptide for injury recovery?
None is proven. BPC-157 has the most animal research for tendon, ligament, muscle and bone, with about 30 people in human pilots. TB-500 beat BPC-157 on tendon strength in one rat test.
Does BPC-157 heal tendons?
In rats, many studies say yes. In people, no controlled trial exists. The human data is about 30 patients in three small uncontrolled pilots, rated very low certainty.
Is TB-500 better than BPC-157?
In one 32-rat Achilles study, only TB-500 reached significance on tendon strength, and giving both added nothing. No human trial compares them.
What is the best peptide for a muscle injury?
No peptide is proven for muscle injury in people. The main data is a rat study of quadriceps torn off the bone, which reported better walking and less stiffness (contracture) with oral BPC-157.
Do peptides help joint pain?
Semaglutide, an approved weight-loss drug, reduced knee osteoarthritis pain in a 68-week trial of 407 adults with obesity, largely through weight loss. No other peptide has comparable trial data.
Can growth hormone peptides speed injury healing?
Not shown. CJC-1295 raises growth hormone and IGF-1 levels, but no trial shows faster injury repair, and FDA lists serious adverse events for it.
Are injury recovery peptides allowed in sport?
No. WADA bans BPC-157 under S0 (non-approved substances) and TB-500 under its growth-factor class, so tested athletes cannot use either.
Should you use peptides instead of rehab?
No. A 2026 sports medicine review concluded peptide supplements should not replace or add to standard orthopaedic care, because their benefits are unproven in humans.
Sources
Show references (17)Hide references
- Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg 2026. Source
- Bicer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg 2026. Source
- Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med 2024. Source
- Tewari K, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med 2026. Source
- Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg 2026. Source
- Mateescu DM, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational barriers. Pharmaceutics 2026. Source
- Adnan SB, et al. Exploring the role of tripeptides in wound healing and skin regeneration: a comprehensive review. Int J Med Sci 2025. Source
- Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med 2026. Source
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. Source
- Villegas Meza AD, et al. Injectable peptides in sports medicine: a structured narrative review of evidence, safety, and antidoping implications. JBJS Rev 2026. Source
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (category 2). Page current as of 22 April 2026. Source
- Fornaro M, et al. MGF peptide has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab 2014. Source
- WADA. The 2026 Prohibited List. Source
- Mendell JR, et al. Phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther 2015. Source
- BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. 28 October 2026. Source
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007. Source
- Matek D, et al. Stable gastric pentadecapeptide BPC 157 as therapy after surgical detachment of the quadriceps muscle from its attachment. Pharmaceutics 2025. Source